Obesity White Papers & Case Studies

  1. Rapid Startup Phase 1 Cardiomyopathy CRISPR Gene Therapy 9/25/2025

    Hereditary transthyretin amyloidosis (ATTRv) is very rare, prompting a Phase 1 trial of in vivo CRISPR/Cas9 gene editing to reduce mutant protein and stop cardiomyopathy progression.

  2. Use Of Epiontis ID In A Phase 2 Psoriasis Trial 9/25/2025

    Mirikizumab’s Phase 2 trial explores IL-23 inhibition in psoriasis, measuring immune cell changes to assess its potential for long-term disease control and flare-up prevention.

  3. How AI Is Reshaping Trial Design, Execution, And Disclosure 9/25/2025

    AI has quietly embedded itself into the operational heart of clinical development, where it is accelerating decisions, reducing manual burden, and improving outcomes.

  4. Decentralized And Community-Based Solutions Driving Women's Healthcare 9/24/2025

    Clinical trials should reflect the affected population by reducing participation barriers and bringing trials to patients to increase inclusion and improve real-world data.

  5. Redefining Accessibility For Pediatric Patients 9/24/2025

    Explore how meeting patients where they are can redefine what successful pediatric trial delivery looks like.

  6. Achieving End-To-End Clinical Supply Chain Visibility 9/23/2025

    Transform supply chain management by integrating technology solutions and real-time insights to link patient-level data with upstream manufacturing operations.

  7. Streamlining Global Respiratory Trial Complexities With Robust Data Capture Strategy 9/23/2025

    Want to see how eCOA solutions can simplify patient-reported data capture and accelerate global trials? Explore implementation strategies, lessons learned, and measurable results.

  8. Remove This Top Barrier And Stop Losing Clinical Trial Participants 9/23/2025

    Comprehensive travel and concierge support removes barriers to clinical trial participation, easing burdens for patients and sites while boosting retention and research outcomes.

  9. Accelerate Your Clinical Trials In Australia 9/23/2025

    Accelerate your biotech trials in Australia—cut costs by up to 60%, enroll patients in as little as 4–6 weeks, and generate FDA- and EMA-accepted data with no IND required.

  10. A Guide To Streamlining Study Start-Up In Australia 9/23/2025

    Discover the benefits of Australia as a premier destination for multinational sponsors looking to expedite drug development, refine trial design, and establish long-term research partnerships.